Chimerix (CMRX) : Traders are bullish on Chimerix (CMRX) as it has outperformed the S&P 500 by a wide margin of 11.78% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.78%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.84% in the last 1 week, and is up 12.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 9.77% and the 50-Day Moving Average is 11.07%. Chimerix (NASDAQ:CMRX): stock turned positive on Friday. Though the stock opened at $4.47, the bulls momentum made the stock top out at $4.62 level for the day. The stock recorded a low of $4.4 and closed the trading day at $4.54, in the green by 1.57%. The total traded volume for the day was 622,117. The stock had closed at $4.47 in the previous days trading.
The company Insiders own 10.5% of Chimerix shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 10.95% . Institutional Investors own 64.35% of Chimerix shares. During last six month period, the net percent change held by insiders has seen a change of 24.67%.
Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).